Pulse Biosciences’ nPulse™ Technology to be Featured at the Heart Rhythm Society 2026 Annual Meeting

Press Release nPulse™ Technology highlighted in late-breaking feasibility study and live case transmission HAYWARD, Calif.--(BUSINESS WIRE)--Apr. 20, 2026-- Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse™ technology using proprietary nanosecond pulsed field ablation™ (nsPFA™) energy, today announced that its nPulse™ Cardiac Catheter will be prominently featured during the Heart Rhythm Society (HRS) 2026 Annual Meeting, taking place April 23-26 in Chicago, Illinois. At HRS 2026, Pulse Biosciences will present late‑breaking clinical trial updates, highlighting European feasibility study one‑year outcomes of nanosecond PFA using a compliant catheter for the treatment of atrial fibrillation (AF). The Company will also participate in a live case transmission during the PFA Live Case Summit. In addition to its booth and technology suite, the proprietary nsPFA™ Technology will be featured at several events at the HRS 2026 Annual Meeting including: Thursday, April 23, 2026 PFA Live Case Summit – Session II: Live PFA Cases Time: 9:40 a.m. – 11:10 a.m. Location: McCormick Place – Room S406AB Live Case Title: PVI+PWA Using Nanosecond PFA Case Site: Fakultní nemocnice Motol a Homolka, Prague, Czech Republic Case Operators: Jan Petru, MD, and Moritoshi Funasako, MD This live case will demonstrate the use of Pulse Biosciences’ nsPFA™ technology in the treatment of atrial fibrillation, highlighting procedural workflow, lesion delivery, and real‑time performance in a clinical setting. Saturday, April 25, 2026 Late‑Breaking Clinical Science Time: 11:45 a.m. – 11:55 a.m. Location: Room S100AB (Plenary Room) Presentation: One‑year Outcomes of Nanosecond Pulsed Field Ablation Using a Compliant Catheter to Treat Atrial Fibrillation: A Multicenter Experience Presenter: Vivek Reddy, MD, Icahn School of Medicine at Mount Sinai, New York, NY This late‑breaking presentation will report one‑year clinical outcomes from a multicenter experience evaluating nanosecond pulsed field ablation using a compliant catheter to treat atrial fibrillation, contributing important longer‑term data to the evolving PFA landscape. Posters & Oral Abstracts Presentation | Novel Mapping and Ablation Technologies Date: Friday, April 24, 2026 Time: 1:10 p.m. – 1:20 p.m. Location: Heart Rhythm Hub 3 – South Lobby Oral Abstract: Nanosecond Pulsed Field Ablation Using a Compliant Circular Catheter to Treat Atrial Fibrillation: A Multicenter Experience Presenter: Petr Neuzil, Fakultní nemocnice Motol a Homolka, Prague, Czech Republic Featured Poster Session I Date: Friday, April 24, 2026 Time: 3:15 p.m. – 5:15 p.m. Location: Abstract Pavilion – Exhibit Hall Abstract: Effects of Dose and Catheter Orientation on Focal Nanosecond Pulsed Field Ablation Lesions: A Preclinical Study Presenter: Masaya Shinohara, Icahn School of Medicine at Mount Sinai About Pulse Biosciences® Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the intention as well as potential to improve the quality of life for patients. The Company’s proprietary nPulse™ technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent non-cellular tissue as well as initiating regulated cell death. The Company is actively pursuing the development of its nPulse technology for use in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers. Pulse Biosciences, nPulse, Vybrance, CellFX, Nano-Pulse Stimulation, NPS, nsPFA, CellFX nsPFA and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in the United States and other countries. View source version on businesswire.com: https://www.businesswire.com/news/home/20260420628292/en/ Investors: Pulse Biosciences, Inc. Jon Skinner, CFO [email protected] Or Gilmartin Group Philip Trip Taylor 415.937.5406 [email protected] Source: Pulse Biosciences